The sky s the limit. If you have all the prerequisites it is possible and the odds are better. Most drug companies are using these techniques. It should also be noted that the genomic database is highlighting individual DNA differences that may contribute to disease. So it is likely that drug design will also become more individualised.
Pharmaceutical companies do have a responsibility to their investors.
But universities are focusing on diseases of developing countries such as malaria and dengue fever. The problem is not limited to this technique. Protein structures are generally determined using X-ray crystallography. High-throughput crystallography is being developed to increase the speed. It is an imaging technique that can be used if you can crystallise the protein.